A customer in (b)(6) notified biomerieux of discrepant results associated with vitek 2 ast-ys07 test kit involving voriconazole for one isolate, candida albicans, from an external quality control neqas sample (distribution 3789 - strain 2983).(b)(4) expected voriconazole resistant ( mic >8 mg/l r-) but the customer obtained voriconazole sensitive (<=0.12).Customer results from columbia blood agar were voriconazole mic <=0.125 mg/l s (twice).There was no patient injury or any adverse event associated with this issue.An internal biomerieux investigation was conducted.Broth microdilution (the reference method for voriconazole development) was performed to determine the intended result, compared with ast-ys07 cards.Two (2) different lots of ast-ys07 cards from sda and cos bmx media.Broth microdilution provided a voriconazole mic >16 mg/l r.On vitek 2, biomerieux obtained results as follows: from sda media and on two (2) ast-ys07 lots: voriconazole mic = 1 s.From cos media and on one (1) ast-ys07 lot: voriconazole mic <=0.125 s.Vitek 2 voriconazole results (<=0.125 - 1 mg/l s) are essential agreement errors (gap >2 doubling dilutions with the reference mic).Biomerieux duplicated the customer's results.Complaint history was reviewed with no trends noted.The investigation concluded the discrepancy involved an atypical strain.In addition, in the final report from (b)(4), voriconazole was not graded since the level of concordance voriconazole (59%) did not reach the requisite 80% of participants.
|